FluoretiQ secures £1.1m in pre-series A funding to advance rapid bacterial diagnostics
The round was led by Deepbridge Capital to help manufacture trial units for a new urinary tract infection diagnostic device.
Share allotment filed at Companies House
University of Bristol spin-out developing rapid diagnostic platforms to identify bacterial infections and support appropriate antibiotic prescriptions.
Bristol-based diagnostics developer FluoretiQ has secured £1.1m in pre-series A funding to manufacture trial units for its rapid urinary tract infection detection device. The capital injection will allow the firm to advance production of its proprietary NANOPLEX platform, which delivers laboratory-quality results for bacterial infections in a fraction of standard times.
The investment was led by Deepbridge Capital, with contributions from MAINStream, OION, SAIC, and existing backers. The fresh funds arrive as global concerns mount regarding antimicrobial resistance, positioning the company to address pressing clinical needs for fast diagnostic tools.
From the founder
"Recent headlines in the LANCET also highlight the need for urgent action to get solutions to preserve the efficacy of current and future antibiotics. These funds will enable us to build cutting-edge, rapid diagnostic products that enable true antibiotic stewardship. We’re so fortunate to have a growing list of committed and visionary investors."
Neciah Dorh
CEO at FluoretiQ
Investor perspective
"FluoretiQ perfectly represents the type of highly innovative and growth-focused companies Deepbridge Capital is committed to supporting within the sector-specific Deepbridge Life Sciences EIS fund; a great example of the importance of the Enterprise Investment Scheme. Neciah has built a great team, eager to take on the significant challenge this market demands, and we are pleased to be working with them on this next exciting stage of their journey."
Savvas Neophytou
Partner & Head of Life Sciences, Deepbridge
Use of funds
- 01Continue product development
